Journey Medical (DERM) Cash from Financing Activities (2021 - 2026)
Journey Medical (DERM) posted Cash from Financing Activities of $220000.0 for Q1 2026, down 95.95% on a QoQ basis from $5.4 million in Q4 2025, and down 93.88% year-over-year from $3.6 million in Q1 2025.
Journey Medical (DERM) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Journey Medical's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $220000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 93.88% year-over-year to $220000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (down 32.21% YoY) and the FY2025 annual result came in at $16.2 million, down 4.51% from the prior year.
- Cash from Financing Activities was $220000.0 for Q1 2026 at Journey Medical, down from $5.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $19.2 million in Q4 2023 and bottomed at -$13.1 million in Q2 2023.
- A 5-year average of $2.7 million and a median of $1.6 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 11890.99% — and 2024, when it soared 3048.08%.
- Journey Medical's Cash from Financing Activities stood at $948000.0 in 2022, then surged by 1926.37% to $19.2 million in 2023, then plunged by 44.72% to $10.6 million in 2024, then slumped by 48.9% to $5.4 million in 2025, then plunged by 95.95% to $220000.0 in 2026.
- Business Quant data shows DERM's Cash from Financing Activities at $220000.0 in Q1 2026, $5.4 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Journey Medical | 179.67 Mn | 152.45 Mn | 9.70 Mn | 220,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 220,000.00 |
| Mar 31, 2026 | 220,000.00 |
| Dec 31, 2025 | 5.43 Mn |
| Dec 31, 2025 | 5.43 Mn |
| Sep 30, 2025 | 7.04 Mn |
| Sep 30, 2025 | 7.04 Mn |
| Jun 30, 2025 | 165,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.60 Mn |
| Dec 31, 2024 | 10.62 Mn |
| Dec 31, 2024 | 10.62 Mn |
| Sep 30, 2024 | -294,000.00 |
| Sep 30, 2024 | -294,000.00 |
| Jun 30, 2024 | 5.03 Mn |
| Jun 30, 2024 | 5.03 Mn |
| Mar 31, 2024 | 1.64 Mn |
| Mar 31, 2024 | 1.64 Mn |
| Dec 31, 2023 | 19.21 Mn |
| Dec 31, 2023 | 19.21 Mn |